125016-87-7

Upstream product

• 67-56-1 methanol 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 611-94-9 4-Methoxybenzophenone 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 40615-35-8 4,4'-dimethoxytrityl alcohol 
• 163759-49-7 2'-O-(2-methoxyethyl)-5-methyluridine 
• 124-41-4 sodium methylate 

Downstream Products

• 40615-35-8 4,4'-dimethoxytrityl alcohol 
• 1542574-89-9 O^5'-(4,4’-dimethoxytrityl)-N²-(dimethylformamidine)-2-aminothieno[3,4-d]pyrimidine 

Relevant academic research and scientific papers

The Mechanism of Deamination of Methoxy Substituted Tritylammonium Ions in Methanolic Aqueous Acid

In methanolic aqueous acid, methoxy-substituted tritylammonium ions undergo heterolysis to give an equilibrium mixture of the substituted trityl cation, the corresponding alcohol (and methyl ether), and the ammonium cation via an SN1 mechanism; the detection of a reaction channel first order in hydronium ions may implicate substituted trityl cation-ammonia (ion-molecule) pairs as reactive intermediates.

Antisense modulation of resistin expression

Antisense compounds, compositions and methods are provided for modulating the expression of resistin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding resistin. Methods of using these compounds for modulation of resistin expression and for treatment of diseases associated with expression of resistin are provided.

Antisense modulation of G protein-coupled receptor 12 expression

Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor 12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor 12. Methods of using these compounds for modulation of G protein-coupled receptor 12 expression and for treatment of diseases associated with expression of G protein-coupled receptor 12 are provided.

Antisense modulation of PTPRA expression

Antisense compounds, compositions and methods are provided for modulating the expression of PTPRA. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPRA. Methods of using these compounds for modulation of PTPRA expression and for treatment of diseases associated with expression of PTPRA are provided.

Antisense modulation of phosphotyrosyl phosphatase activator expression

Antisense compounds, compositions and methods are provided for modulating the expression of phosphotyrosyl phosphatase activator. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phosphotyrosyl phosphatase activator. Methods of using these compounds for modulation of phosphotyrosyl phosphatase activator expression and for treatment of diseases associated with expression of phosphotyrosyl phosphatase activator are provided.

Antisense modulation of Ran GTPase activating protein 1 expression

Antisense compounds, compositions and methods are provided for modulating the expression of Ran GTPase activating protein 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Ran GTPase activating protein 1. Methods of using these compounds for modulation of Ran GTPase activating protein 1 expression and for treatment of diseases associated with expression of Ran GTPase activating protein 1 are provided.

Antisense modulation of KIAA1531 protein expression

Antisense compounds, compositions and methods are provided for modulating the expression of KIAA1531 protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding KIAA1531 protein. Methods of using these compounds for modulation of KIAA1531 protein expression and for treatment of diseases associated with expression of KIAA1531 protein are provided.

Antisense modulation of G protein-coupled receptor 6 expression

Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor 6. Methods of using these compounds for modulation of G protein-coupled receptor 6 expression and for treatment of diseases associated with expression of G protein-coupled receptor 6 are provided.

Antisense modulation of PPP2R1A expression

Antisense compounds, compositions and methods are provided for modulating the expression of PPP2R1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PPP2R1A. Methods of using these compounds for modulation of PPP2R1A expression and for treatment of diseases associated with expression of PPP2R1A are provided.

Antisense modulation of requiem expression

Antisense compounds, compositions and methods are provided for modulating the expression of requiem. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding requiem. Methods of using these compounds for modulation of requiem expression and for treatment of diseases associated with expression of requiem are provided.